Aseptuva raises $2.9M seed
Announced 18 September 2026
◆ The Round
Aseptuva raised $2.9M in seed funding, announced on 18 September 2026, led by Simon Michel, Roger Nitsch, Armin Diethelm, Auxinam, weInvest, with participation from Valuemaker, Fortyone. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.
◆ About Aseptuva
Swiss-UK medtech startup developing targeted Far-UVC disinfection technology to prevent hospital-acquired infections linked to intravenous catheters. Aseptuva is based in Switzerland and currently at seed stage, operating in Medtech.
◆ Investors
LeadSimon Michel, Roger Nitsch, Armin Diethelm, Auxinam, weInvest
ParticipationValuemaker, Fortyone
◆ Market context
This funding event is a citable node in Fusion42's market graph: it links Aseptuva's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.
◆ Explore the market
◆ FAQ
How much did Aseptuva raise?
Aseptuva raised $2.9M in its seed round, announced 2026-09-18.
Who invested in Aseptuva's seed round?
The round was led by Simon Michel, Roger Nitsch, Armin Diethelm, Auxinam and weInvest, with participation from Valuemaker and Fortyone.
What does Aseptuva do?
Swiss-UK medtech startup developing targeted Far-UVC disinfection technology to prevent hospital-acquired infections linked to intravenous catheters.
Verified 18 September 2026 · Sources: public filings